( ffected joints to prevent disability. ...)Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis,Health

Traditional treatments for RA include nonsteroidal anti-Inflammatory drugs (NSAIDs), corticosteroids and disease modifying antirheumatic
drugs (DMARDs), with biological therapies a more recent addition to the list of treatment options. Anti-TNF (TNF-alpha; Tumour Necrosis
Factor) therapies are specific types of monoclonal antibody (biological therapies) which have been approved for use in patients with RA. They may be given alone but are usually given in combination with methotrexate or another immunosuppressant. Anti-TNF therapies
have proven to be effective treatments, with the potential to prevent joint damage. They work by inhibiting the action of TNF-alpha, an
inflammatory mediator, either directly or indirectly responsible for damaging the joint.[6]

About CIMZIA(TM) (certolizumab pegol)
CIMZIA(TM) (certolizumab pegol) is an investigational drug product. CIMZIA(TM) is the first and only PEGylated Fc-free anti-TNF (Tumour Necrosis Factor), and is being evaluated in RA at a dosing of once every two weeks and once every four weeks, via subcutaneous
administration. CIMZIA(TM) has demonstrated efficacy without the possible cytotoxicity mediated by the Fc portion present in conventional anti-TNFs.

CIMZIA(TM) has a high affinity for human TNF-alpha, selectively targeting TNF-alpha in inflamed tissue. Over the past decade,
TNF-alpha has emerged as a major target of basic research and clinical investigation. This cytokine plays a key role in mediating
pathological inflammation, and excess TNF-alpha production has been directly implicated in a wide variety of diseases.

UCB filed a Biologics License Application (BLA) with the Food and Drug Administration (FDA) for CIMZIA(TM) in the treatment of Crohn's disease on February 28, 2006 and on April 28, 2006 submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) for the same
'"/>